IDH1 and central nervous system cancer: Ivosidenib is trying to expand to solid and other hematological tumors with an IDH1 mutation, such as glioma, pancreatic adenocarcinoma, and myedysplastic syndrome (NCT02073994, NCT05209074, and NCT03839771).